checkAd

Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results

Nachrichtenquelle: globenewswire
24.02.2021, 22:05  |  384   |   |   

Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million

Full year revenue grows 98% year-over-year to $1,094.0 million and total visits increase 156% to 10.6 million

Issues 2021 first-quarter and full-year guidance

PURCHASE, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported strong financial results for the fourth quarter and full year ended December 31, 2020.

“As virtual care shifted to become a consumer expectation in 2020, Teladoc Health not only met the rapidly growing demand, but we transformed our company to define a new category of whole-person virtual care,” said Jason Gorevic, chief executive officer of Teladoc Health. “By accelerating our mission to transform the health care experience, we exceeded our fourth-quarter and full-year 2020 expectations and see strong momentum across our global business in 2021 as the market embraces the breadth and depth of our unique capabilities.”

Financial Highlights for the Fourth Quarter and Full Year Ended December 31, 2020

                                       
Revenue                                      
($ thousands, unaudited)                                      
    Quarter Ended   Year over Year   Year Ended  Year over Year  
    December 31,   Growth   December 31,
  Growth  
                           
       2020      2019             2020      2019      
Access Fees Revenue                                      
U.S.   $ 282,826   $ 98,052   188   %   $ 737,408   $ 356,656   107   %  
International     33,131     28,924   15   %     124,392     106,640   17   %  
Total     315,957     126,976   149   %     861,800     463,296   86   %  
                                       
Visit Fee Revenue                                      
U.S.     53,149     29,222   82   %     206,093     88,669   132   %  
International     113     291   (61 ) %     818     1,342   (39 ) %  
Total     53,262     29,513   80   %     206,911     90,011   130   %  
                                       
Other                                      
U.S.     13,589     0   N/M       23,888     0   N/M    
International     513     0   N/M       1,363     0   N/M    
Total     14,102     0   N/M       25,251     0   N/M    
                                       
Total Revenue   $ 383,321   $ 156,489   145   %   $ 1,093,962   $ 553,307   98   %  
 

N/M – Not meaningful

                 
Membership and Visit Fee Only Access                
(millions)                
    December 31,   Growth  
       2020      2019         
U.S. Paid Membership   51.8   36.7   41 %  
                 
U.S. Visit Fee Only Access   21.3   19.3   10 %  
                 
Chronic Care Enrollment   0.6     N/M    
   


                                     
Visits                                    
(thousands)                                
  Quarter Ended   Year over Year   Year Ended   Year over Year  
  December 31,   Growth   December 31,   Growth  
  2020        2019            2020        2019        
U.S. Visits   2,515       975     158 %     8,820       3,104     184 %  
International Visits   440       264     67 %     1,771       1,034     71 %  
Total Visits   2,955       1,239     139 %     10,591       4,138     156 %  
                                     
Utilization   17.7 %     9.5 %   826 pt     16.0 %     9.3 %   664 pt  
                                     
Platform-Enabled Sessions*   1,089           N/M       2,076           N/M    
                                     
Total Visits & Sessions Provided & Enabled   4,044       1,239     226 %     12,667       4,138     206 %  
                                     

* Platform-Enabled Session is a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our client’s patient, or between care providers. We believe platform-enabled sessions are an indicator of the value our clients derive from the platform they license from us in order to facilitate virtual care.

  • Net loss was $(394.0) million for the fourth quarter 2020 compared to $(19.0) million for the fourth quarter 2019. Net loss was $(485.1) million for the full year 2020 compared to $(98.9) million for the full year 2019. The fourth quarter and full year 2020 includes $57.6 million and $88.2 million, respectively, of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. Net loss for the fourth quarter and full year 2020 also includes $54.7 million of stock-based compensation related to Livongo stock awards that continue to vest after the merger. Net loss also includes an income tax benefit of $85.5 million for the fourth quarter 2020 and $90.9 million for the full year 2020.
  • Net loss per basic and diluted share was $(3.07) for the fourth quarter 2020 compared to $(0.26) for the fourth quarter 2019. Net loss per basic and diluted share was $(5.36) for the full year 2020 compared to $(1.38) for the full year 2019. The fourth quarter and full year 2020 includes $0.45 and $0.97 per share, respectively, of acquisition and integration related costs as well as $2.59 and $3.66 per share, respectively, of accelerated stock-based awards expense related to the merger with Livongo. Net loss per basic and diluted share for the fourth quarter and full year 2020 also includes $0.43 and $0.60 per share, respectively, of stock-based compensation related to Livongo stock awards that continue to vest after the merger. Net loss per basic and diluted share for the fourth quarter and full year 2020 also includes an income tax benefit of $0.67 and $1.00 per share, respectively.
  • GAAP Gross margin, which includes depreciation and amortization, was 67.2 percent for the fourth quarter 2020 and 63.8 percent for the fourth quarter 2019. GAAP Gross margin which includes depreciation and amortization, was 63.1 percent for the full year 2020 and 65.8 percent for the full year 2019.
  • Adjusted Gross margin was 67.9 percent for the fourth quarter 2020 compared to 64.6 percent for the fourth quarter 2019. Adjusted Gross margin was 64.3 percent for the full year 2020 compared to 66.7 percent for the full year 2019.
  • EBITDA was a loss of $(421.5) million for the fourth quarter 2020 compared to a loss of $(5.7) million for the fourth quarter 2019. EBITDA for the fourth quarter 2020 includes $57.6 million of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. EBITDA was a loss of $(436.9) million for the full year 2020 compared to a loss of $(41.5) million for the full year 2019. EBITDA for the full year 2020 includes $88.2 million of acquisition and integration related costs as well as $331.7 million of accelerated stock-based awards expense related to the merger with Livongo. EBITDA for the fourth quarter and full year 2020 also includes $54.7 million of stock-based compensation related to Livongo stock awards that continue to vest after the merger.
  • Adjusted EBITDA was $50.4 million for the fourth quarter 2020 compared to $15.2 million for the fourth quarter 2019. Adjusted EBITDA was $126.8 million for the full year 2020 compared to $31.8 million for the full year 2019. Adjusted EBITDA was higher by $5.4 million in the fourth quarter and full year 2020, primarily related to lower expenses on Livongo devices as a result of the merger.

A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook
Teladoc Health provides guidance based on current market conditions and expectations. Given the uncertainty of the expected path of the COVID-19 pandemic as well as the broader economic impact, our updated guidance is based on what we know today. As this is an evolving situation, circumstances are likely to change, but we believe our guidance ranges provide a reasonable baseline for 2021 financial performance.

For the first-quarter 2021, we expect:

  • Total revenue to be in the range of $445 million to $455 million.
  • EBITDA to be in the range of $(46) million to $(43) million.
  • Adjusted EBITDA to be in the range of $45 million to $48 million, including an estimated $7 million in lower expenses primarily related to Livongo devices as a result of the merger.
  • Total U.S. paid membership to be in the range of 51 million to 52 million members and visit fee only access to be available to 22 to 23 million individuals, including 2 to 3 million individuals on a temporary basis.
  • Total visits to be between 2.9 million and 3.1 million.

For the full-year 2021, we expect:

  • Total revenue to be in the range of $1.95 billion to $2.0 billion.
  • EBITDA to be in the range of $(110) million to $(90) million.
  • Adjusted EBITDA to be in the range of $255 million to $275 million, including an estimated $20 million in lower expenses primarily related to Livongo devices as a result of the merger.
  • Total U.S. paid membership to be in the range of 52 million to 54 million members and visit fee only access to be available to 22 to 23 million individuals, including 2 to 3 million individuals on a temporary basis.
  • Total visits to be between 12 million to 13 million.

Quarterly Conference Call

The fourth quarter and full year 2020 earnings conference call and webcast will be held Wednesday, February 24, 2021 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-833-968-2101 for U.S. participants, or 1-236-714-2089 for international participants, and referencing Conference ID Number: 1127504; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link, and will remain available for approximately 90 days.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Ranked best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; and (v) changes to our abilities to recruit and retain qualified providers into our network; and (vi) the impact of the COVID-19 pandemic on our operations, demand for our services and general economic conditions, as well as orders, directives and legislative action by local, state, federal and foreign governments in response to the spread of COVID-19. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)

             
    December 31,   December 31,
       2020        2019  
           
Assets            
Current assets:            
Cash and cash equivalents   $ 733,324     $ 514,353  
Short-term investments     53,245       2,711  
Accounts receivable, net of allowance of $6,412 and $3,787, respectively     169,281       56,948  
Inventories     56,498       0  
Prepaid expenses and other current assets     47,259       13,990  
Total current assets     1,059,607       588,002  
Property and equipment, net     28,551       10,296  
Goodwill     14,581,255       746,079  
Intangible assets, net     2,020,864       225,453  
Operating lease - right-of-use assets     46,647       26,452  
Other assets     18,357       6,545  
Total assets   $ 17,755,281     $ 1,602,827  
Liabilities and stockholders’ equity            
Current liabilities:            
Accounts payable   $ 46,030     $ 9,075  
Accrued expenses and other current liabilities     83,657       34,440  
Accrued compensation     94,593       34,201  
Deferred revenue-current     52,356       12,465  
Advances from financing companies     13,453       0  
Current portion of long-term debt     42,560       0  
Total current liabilities     332,649       90,181  
Other liabilities     1,616       9,239  
Operating lease liabilities, net of current portion     43,142       24,994  
Deferred revenue, net of current portion     2,449       2,300  
Advances from financing companies, net of current portion     9,926       0  
Deferred taxes     102,103       21,678  
Convertible senior notes, net     1,379,592       440,410  
Commitments and contingencies            
Stockholders’ equity:            
Common stock, $0.001 par value; 300,000,000 shares and 150,000,000 shares authorized as of December 31, 2020 and December 31, 2019, respectively; 150,281,099 shares and 72,761,941 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively     150       73  
Additional paid-in capital     16,857,797       1,538,716  
Accumulated deficit     (992,661 )     (507,525 )
Accumulated other comprehensive loss     18,518       (17,239 )
Total stockholders’ equity     15,883,804       1,014,025  
Total liabilities and stockholders’ equity   $ 17,755,281     $ 1,602,827  

CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data, unaudited)

                         
    Quarter Ended December 31,   Year Ended December 31,
    2020        2019        2020        2019  
Revenue   $ 383,321     $ 156,489     $ 1,093,962     $ 553,307  
Expenses:                        
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)     122,942       55,355       390,829       184,465  
Operating expenses:                        
Advertising and marketing     93,751       25,356       226,146       109,697  
Sales     93,942       16,751       154,052       64,915  
Technology and development     92,697       16,246       164,941       64,644  
Legal and regulatory     2,610       1,523       8,876       6,762  
Acquisition and integration related costs     57,550       2,477       88,236       6,620  
General and administrative     341,375       44,482       497,808       157,694  
Depreciation and amortization     36,960       9,887       69,495       38,952  
Total expenses     841,827       172,077       1,600,383       633,749  
Loss from operations     (458,506 )     (15,588 )     (506,421 )     (80,442 )
Loss on extinguishment of debt     99       0       9,077       0  
Interest expense, net     20,819       7,581       60,495       29,013  
Net loss before taxes     (479,424 )     (23,169 )     (575,993 )     (109,455 )
Income tax benefit     (85,457 )     (4,125 )     (90,857 )     (10,591 )
Net loss   $ (393,967 )   $ (19,044 )   $ (485,136 )   $ (98,864 )
                         
Net loss per share, basic and diluted   $ (3.07 )   $ (0.26 )   $ (5.36 )   $ (1.38 )
                         
Weighted-average shares used to compute basic and diluted net loss per share     128,298,005       72,564,855       90,509,229       71,844,535  

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)

             
    Year Ended December 31,
       2020     2019  
Cash flows (used in) provided by operating activities:                     
Net loss   $ (485,136 )   $ (98,864 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:            
Depreciation and amortization     69,495       38,952  
Depreciation of rental equipment     1,697       0  
Amortization of right-of-use assets     6,895       6,000  
Allowance for doubtful accounts     5,284       2,665  
Stock-based compensation     475,531       66,702  
Deferred income taxes     (90,158 )     (10,868 )
Accretion of interest     45,296       25,438  
Loss on extinguishment of debt     9,077       0  
Change in fair value of contingent consideration     (1,009 )     1,248  
Changes in operating assets and liabilities:            
Accounts receivable     (21,091 )     (15,884 )
Prepaid expenses and other current assets     (12,565 )     (2,685 )
Inventory     (24,732 )     0  
Other assets     (8,135 )     (105 )
Accounts payable     (87,995 )     905  
Accrued expenses and other current liabilities     20,125       10,026  
Accrued compensation     34,819       4,546  
Deferred Revenue     17,751       4,815  
Operating lease liabilities     (6,300 )     (2,417 )
Other liabilities     (2,360 )     (605 )
Net cash (used in) provided by operating activities     (53,511 )     29,869  
Cash flows (used in) provided by investing activities:            
Capital expenditures     (4,024 )     (3,510 )
Capitalized software development costs     (22,018 )     (7,390 )
Proceeds from marketable securities     2,496       52,100  
Investment in securities     0       (5,000 )
Acquisitions of business, net of cash acquired     (567,429 )     (11,187 )
Net cash (used in) provided by investing activities     (590,975 )     25,013  
Cash flows provided by financing activities:            
Net proceeds from the exercise of stock options     54,314       33,283  
Proceeds from issuance of 2027 Notes     1,000,000       0  
Payment of issuance costs of 2027 Notes     (24,070 )     0  
Repurchase of 2022 Notes     (228,153 )     0  
Proceeds from the sale of capped call related to the Livongo Notes     91,659       0  
Proceeds from advances from financing companies     6,002       0  
Payment from customers against advances from financing companies     (8,635 )     0  
Payment of assumed indebtedness     (10,000 )     0  
Proceeds from employee stock purchase plan     4,722       3,380  
Cash paid for withholding taxes on stock-based compensation, net     (26,703 )     (1,569 )
Net cash provided by financing activities     859,136       35,094  
Net increase in cash and cash equivalents     214,650       89,976  
Foreign exchange difference     4,321       388  
Cash and cash equivalents at beginning of the period     514,353       423,989  
Cash and cash equivalents at end of the period   $ 733,324     $ 514,353  
             
Income taxes paid   $ 1,324     $ 1,310  
             
Interest paid   $ 14,890     $ 12,224  

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with GAAP, we use adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA, which are non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as the primary measure of our performance.

Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which is shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue. We believe that these measures provide investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, depreciation, amortization and loss on extinguishment of debt. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis. For presentation purposes, foreign exchange gain or loss is included in interest expense, net in our consolidated statement of operations.

Adjusted EBITDA consists of net loss before interest, foreign exchange gain or loss, taxes, depreciation, amortization, stock-based compensation, loss on extinguishment of debt and acquisition and integration related costs. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA may vary from that of others in our industry. None of adjusted gross profit, adjusted gross margin, EBITDA nor adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with GAAP as measures of performance.

Adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • Adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;
  • Adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;
  • EBITDA and adjusted EBITDA do not reflect the significant interest expense on our debt;
  • EBITDA and adjusted EBITDA eliminate the impact of income taxes on our results of operations;
  • EBITDA and Adjusted EBITDA do not reflect the loss on extinguishment of debt;
  • Adjusted EBITDA does not reflect the significant acquisition and integration related costs related to mergers and acquisitions;
  • Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and
  • other companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA differently than we do, limiting the usefulness of adjusted these measures as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

We have not reconciled EBITDA or adjusted EBITDA guidance to GAAP net income (loss) because we do not provide guidance on GAAP net income (loss) or the reconciling items between EBITDA and adjusted EBITDA and GAAP net income (loss) as a result of the uncertainty regarding, and the potential variability of, certain of these items, the effect of which may be significant. Accordingly, a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure is not available without unreasonable effort.

The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:

Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin
(In thousands, unaudited)

                           
    Quarter Ended   Year Ended   
    December 31,   December 31,  
       2020        2019        2020        2019       
Revenue   $ 383,321     $ 156,489     $ 1,093,962     $ 553,307    
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)     (122,942 )     (55,355 )     (390,829 )     (184,465 )  
Depreciation and amortization of intangible assets     (2,846 )     (1,301 )     (12,394 )     (4,580 )  
Gross Profit     257,533       99,833       690,739       364,262    
Depreciation and amortization of intangible assets     2,846       1,301       12,394       4,580    
Adjusted gross profit   $ 260,379     $ 101,134     $ 703,133     $ 368,842    
                           
Gross margin     67.2   %   63.8   %   63.1   %   65.8   %
Adjusted gross margin     67.9   %   64.6   %   64.3   %   66.7   %

The following is a reconciliation of Net Loss, the most directly comparable GAAP financial measure, to EBITDA and Adjusted EBITDA:

Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA
(In thousands, unaudited)

                           
    Quarter Ended   Year Ended   
    December 31,   December 31,  
       2020        2019        2020        2019       
Net loss   $ (393,967 )   $ (19,044 )   $ (485,136 )   $ (98,864 )  
Add:                          
Loss on extinguishment of debt     99       0       9,077       0    
Interest expense, net     20,819       7,581       60,495       29,013    
Income tax benefit     (85,457 )     (4,125 )     (90,857 )     (10,591 )  
Depreciation expense     1,783       682       4,766       3,382    
Amortization expense     35,177       9,205       64,729       35,570    
EBITDA     (421,546 )     (5,701 )     (436,926 )     (41,490 )  
Stock-based compensation     414,380       18,457       475,531       66,702    
Acquisition and integration related costs     57,550       2,477       88,236       6,620    
Adjusted EBITDA   $ 50,384     $ 15,233     $ 126,841     $ 31,832    

Investors:
Patrick Feeley
914-265-7925
pfeeley@teladochealth.com 

Media:
Chris Stenrud
860-491-8821
pr@teladochealth.com


Teladoc Health Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million Full year revenue grows 98% year-over-year to $1,094.0 million and total visits increase 156% to 10.6 million …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel